ARCHIVES

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

Where’s The Money for Local Programs? Everyone Wants To Know

February 28, 1975

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

September 29, 2000

Call to Shift Two-Thirds Of Funds a “Rubber Number,” Bailar Says

June 6, 1997

FDA Can’t Prohibit Distribution of Articles, Books On Off-Label Drug Use, Judge Rules

August 13, 1999

In Brief: Illinois Legislature Votes Nearly $1 Million To ICC; Carolyne Davis Resigns From HCFA Jobs

August 2, 1985

Interview With Departing NCI Director; Advice To His Successor.

July 9, 2010